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Recent approaches to 
pharmacotherapy of personality disorders
Practice points
  Pharmacotherapy of personality disorders should be considered a symptom-focused treatment, targeting 
dimensions of affective dysregulation, impulsive-behavioral dyscontrol and cognitive-perceptual symptoms. 
  To date, randomized controlled trials have been performed in samples of patients with antisocial personality 
disorder, schizotypal personality disorder and borderline personality disorder (BPD). However, the great 
majority of these trials have been conducted in samples with BPD. 
  There is some evidence that mood stabilizers (topiramate, valproate and lamotrigine), second-generation 
antipychotics (olanzapine, aripiprazole), and omega-3 fatty acids can be useful for the treatment of affective 
symptoms and impulsive-behavioral dyscontrol in BPD patients.
  Antipsychotics produced an improvement of psychotic-like symptoms both in patients with BPD and 
schizotypal personality disorder.
  Selective serotonin reuptake inhibitors were found to be effective in decreasing depressed mood, anxiety, and 
anger in BPD patients, mainly with a comorbid major depressive episode. However, recent evidence no longer 
supports their use as first-line treatment of affective symptoms and impulsive-behavioral dyscontrol in BPD. 
  Present studies suffer from important methodological limitations. Thus, further investigations are needed to 
confirm available findings.
SUMMARY A growing number of studies on pharmacotherapy of personality disorders 
have been performed. This article considers controlled trials conducted between 1990 and 
2010, and is directed toward the treatment of personality disorders. Data on borderline 
personality disorder (BPD), antisocial personality disorder and schizotypal personality 
disorder (STPD) were collected and discussed, in order to provide indications for clinical 
practice. Concerning antisocial personality disorder and STPD, available evidence is too 
sparse to propose treatment recommendations. As for BPD, there is some evidence that 
mood stabilizers (topiramate, valproate, and lamotrigine), second-generation antipsychotics 
(olanzapine, aripiprazole), and omega-3 fatty acids can be useful to treat affective symptoms 
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Personality disorders (PDs) are defined as endur­
ing patterns of inner experience and behavior 
causing distress, which lead to maladaptive 
functioning in the areas of emotion, cognition, 
interpersonal relationships and impulse con­
trol [1]. Since the 1980s there has been increas­
ing recognition that PDs can be considered as 
syndromes of interacting dimensional traits that 
arise from psychosocial development and/or 
biological vulnerability [2]. Personality dimen­
sions acquired through social and cultural 
learning are termed character, whereas those 
believed to have a biological origin, genetically 
determined or acquired from overt injury to the 
CNS, are traditionally referred to as tempera­
ment. Temperament involves the biological reg­
ulation of cognition, perception, information 
processing, affect, and impulse, which is carried 
out by neurotransmitter systems. A pharmaco­
logical approach to treatment of PDs is based 
on the ability of medications to modify neuro­
transmitter functions that mediate expression of 
state symptoms and trait vulnerabilities related 
to personality dimensions. 
According to Soloff ’s model [3,4], adopted 
by American Psychiatric Association (APA) 
guidelines for the treatment of borderline per­
sonality disorder (BPD) [1], pharmacotherapy of 
PDs may be reframed as symptom­specific treat­
ment, focused on a few target dimensions, such 
as affective dysregulation, cognitive­perceptual 
symptoms and impulsive­behavioral dyscontrol. 
Pharmacotherapy is an important adjunc­
tive treatment in the overall management of 
patients with severe PDs, but is not a primary 
treatment for problems of character or mal­
adaptive interpersonal relationships, which are 
the main focus of psychotherapy. Thus, medi­
cation should only be part of a comprehensive 
treatment plan including psychotherapy and 
social work, which should be developed consid­
ering the individual psychopathology, severity 
of illness and functioning.
Pharmacotherapy of PDs is still a relatively 
new and evolving clinical practice. It is impor­
tant to note that the US FDA has not approved 
any medication for the treatment of PDs yet. 
and impulsive-behavioral dyscontrol. Antipsychotics showed positive effects on cognitive 
symptoms both in patients with BPD and STPD. Selective serotonin reuptake inhibitors were 
found effective in decreasing depressed mood, anxiety and anger in BPD patients, mainly 
in subjects with a concomitant affective disorder. Effects of antidepressants on impulsive 
behaviors are uncertain. Further studies are needed to improve methods of trials and confirm 
these findings. 
Randomized controlled trials (RCTs) on 
treatment of PDs are limited and the great 
majority of these trials have been conducted in 
patients with borderline PD. Nevertheless, these 
results have made possible the development 
of treatment guidelines that provide detailed 
recom mendations for clinicians dealing with 
PD patients. Before presenting and discussing 
contents of available treatment guidelines, we 
will review double­blind randomized compari­
sons of drug versus placebo or drug versus drug 
published between 1990 and 2010 and directed 
at the treatment of PDs. Available controlled 
studies are focused on BPD, antisocial personal­
ity disorder (ASPD) and schizotypal personal­
ity disorder (STPD). Results of studies on each 
cluster of PDs are separately described. 
Treatment of STPD 
Schizotypal PD is generally considered a schizo­
phrenia spectrum disorder [5,6]. Similarities 
between STPD and schizophrenia in phenomeno­
logy and biological correlates have provided the 
rationale for testing the efficacy of classical neuro­
leptics (flupentixol, thiothixene and haloperidol) 
in patients with STPD since 1980 [7–9]. Patients 
in these studies gained modest improvement after 
treatment with low doses of neuroleptics, with 
the greatest effects on psychotic­like symptoms 
and anxiety. 
Concerning second­generation antipsychotics, 
few data are available [10,11] and only two RCTs on 
risperidone have been published [12,13]. 
Koenigsberg et al. performed a 9­week RCT 
on 25 STPD patients (five subjects had comor­
bid BPD), randomly assigned to risperidone 
(0.25–2.00 mg/day) or placebo [12]. Patients 
in the risperidone group showed a significant 
decline in the Positive and Negative Syndrome 
Scale (PANSS) total, negative, positive, and gen­
eral scores, compared with placebo. Significant 
differences were not found with the Schizotypal 
Personality Disorder Questionnaire (SPQ), the 
Hamilton Depression Rating Scale (HAMD) 
and the Clinical Global Impression (CGI). 
Moreover, seven of the 15 patients in the risperi­
done group dropped out because of side effects. In 
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recent years, there has been growing interest for 
treatment of cognitive performances measured by 
neuropsychological tests in schizophrenia spec­
trum disorders, such as STPD. McClure et al. 
enrolled 31 STPD patients, randomly assigned 
to risperidone (0.25–2.00 mg/day) or placebo, 
in order to evaluate the effects of risperidone on 
their cognitive performance [13]. Several patients 
in both groups dropped out and only 20 subjects 
completed all 12 weeks of the trial. There were no 
significant differences between the two treatment 
groups in improvement of neuropsychological 
functions (spatial and verbal working memory, 
vigilance, spatial memory, work list learning) 
from baseline. More encouraging results on 
these outcome measures were obtained by the 
same research group [14,15] using dopamine and 
adrenaline agonists. McClure et al. performed a 
double­blind, placebo­controlled trial of guanfa­
cine on 29 STPD patients, supporting its efficacy 
in improving context processing [14]. In another 
RCT, they administered pergolide to 25 patients 
with STPD and found a significant improvement 
in visual spatial working memory, executive 
functioning, verbal learning and memory [15].
In conclusion, preliminary studies performed 
in STPD patients (Table 1) suggest a reduction 
of psychotic­like symptoms with antipsychotics 
and an improvement of cognitive performances 
measured by neuropsychological tests with dopa­
mine and adrenaline agonists. Nevertheless, most 
studies suffer from high drop­out rates because 
of considerable sensitivity to side effects in this 
population. Moreover, some patients in these 
studies had concomitant BPD [8–10,12]. So, it 
remains unclear whether the reported improve­
ments were due to the medications’ effects on 
BPD­related symptoms. 
Pharmacotherapy of cluster B PDs 
Newer therapies for ASPD have received pre­
liminary testing. Nevertheless most studies 
of patients with cluster B PDs are focused on 
treatment of BPD. 
Results of controlled studies on the efficacy 
of each class of drugs are separately reviewed, 
in order to make clear the different level 
of evidence. 
Treatment of BPD 
  Antidepressants
A considerable number of open­label trials and 
RCTs have been performed to assess the efficacy 
of antidepressants in the treatment of affective 
lability, impulsivity and aggressiveness in BPD 
samples. The following groups of antidepres­
sants have been evaluated: tricyclic antidepres­
sants, monoamino­oxidase inhibitors (MAOIs), 
selective serotonin reuptake inhibitors (SSRIs), 
and serotonin and norepinephrine reuptake 
inhibitors (SNRIs). Concerning tricyclic anti­
depressants and MAOIs, available data [16–19] 
suggest that the efficacy of these drugs in 
patients with BPD is limited, with main effects 
on symptoms of depression. The risk of behav­
ioral toxicity and the potential lethality support 
the preferential use of SSRIs or SNRIs to treat 
these patients. 
Selective serotonin reuptake inhibitors 
Six RCTs testing the efficacy of SSRIs have 
been conducted so far: five studies on fluox­
etine [20–24], one study on f luvoxamine 
(Table 2) [25].
Salzmann and colleagues published a 12­week 
double­blind trial of fluoxetine (20–60 mg/day) 
in 27 patients with BPD or bipolar traits, 
Table 1. Double-blind randomized trials in the treatment of schizotypal personality disorder.
Study (year) Agents Study design Subjects Results (primary outcome) Ref.
Koenigsberg et al. 
(2003)
Risperidone (0.25–2.00 mg/day) 
versus placebo
RCT
9 weeks
25 STPD patients 
(5 BPD)
↓ PANSS total, negative, positive 
and general scores
[12]
McClure et al. (2009) Risperidone (0.25–2.00 mg/day) 
versus placebo
RCT
12 weeks
20 STPD patients No effects on cognitive 
performance 
[13]
McClure et al. (2007) Guanfacine (≤2 mg/day)
versus placebo
RCT
4 weeks
29 STPD patients ↑ context processing ability [14]
McClure et al. (2010) Pergolide (≤3 mg/day)
versus placebo
RCT
4 weeks
25 STPD patients ↑ visual spatial working 
memory, executive functioning, 
and verbal learning 
and memory
[15]
↓: Decrease of; ↑: Increase of; BPD: Borderline personality disorder; PANSS: Positive and Negative Syndrome Scale; RCT: Randomized controlled trial; STPD: Schizotypal 
personality disorder.
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evaluating effects on global functioning, anger 
and depression [21]. Patients had a good level 
of functioning (baseline Global Assessment of 
Symptoms [GAS] scores in the 70s) and did 
not present comorbidity with Axis I or II dis­
orders. In a primary ana lysis, only the anger 
subscale of the Profile of Mood States (POMS) 
and the GAS yielded a statistical improvement 
over placebo in the 22 patients completing 
the trial. In a post hoc ana lysis with correction 
for the strong placebo effect, statistically sig­
nificant differences between treatment condi­
tions were obtained with respect to anger and 
aggression, which appeared to be independent 
of depression. 
Markovitz conducted a 14­week RCT of 
f luoxetine (20–80 mg/day) in a group of 
17 patients with BPD and high co­occurrence of 
affective/anxiety disorders and somatic symp­
toms [20]. Patients receiving fluoxetine improved 
significantly more than those receiving placebo 
on measures of depression, anxiety and global 
symptoms. Measures of impulsive­aggression 
were not included in this study. Comorbidity 
with affective and anxiety disorders limits 
interpretation of results, because SSRIs are 
effective for these disorders independently 
of BPD. 
A double­blind placebo­controlled study by 
Coccaro and Kavoussi focused attention on 
impulsive­aggression as a dimensional construct, 
found across PD categories, but especially char­
acteristic of BPD and other cluster B PDs [22]. 
They enrolled a mixed sample of 40 PD patients 
(approximately a third with a Diagnostic and 
Statistical Manual of Mental Disorders [DSM]­
III­R diagnosis of BPD), all with impulsive­
aggressive behavior and irritability (the female 
group constituted only a quarter of the total 
sample). Comorbid major depression or bipolar 
disorder were excluded, but dysthymic disorder, 
anxiety disorders, alcohol and substance abuse 
were common. Subjects were randomly assigned 
to fluoxetine (20–60 mg/day) or placebo in a 
ratio 2:1 for a 12­week trial. A significant 
improvement with respect to impulsive­aggres­
sive behavior was seen in favor of fluoxetine after 
10 weeks of treatment, but global improvement 
was already significant at week 4 and irritability 
decreased at week 6. 
Table 2. Double-blind randomized trials of selective serotonin reuptake inhibitors in the treatment of borderline 
personality disorder.
Study (year) Agents Study design Subjects Results (primary outcome) Ref.
Markovitz (1995) Fluoxetine
(20–80 mg/day)
versus placebo
RCT
14 weeks
17 BPD patients with 
concomitant Axis I affective 
and anxiety disorders 
↓ anxiety and depression
↓ global symptoms 
[20]
Salzmann et al. (1995) Fluoxetine
(20–60 mg/day)
 versus placebo
RCT
12 weeks
27 BPD patients 
with a good level 
of functioning,
no Axis I or II comorbidity
↓ anger 
↑ global functioning
[21]
Coccaro and Kavoussi 
(1997)
Fluoxetine
(20–60 mg/day) 
versus placebo
RCT
12 weeks
40 patients with PDs (33% 
BPD, 25% female), impulsive-
aggressive behaviors and 
comorbidity with dysthymic 
disorder, anxiety disorders or 
substance abuse
↓ irritability 
↓ impulsive-aggression
↑ global functioning
[22]
Simpson et al. (2004) Fluoxetine (40 mg/day) 
+ DBT versus DBT + 
placebo
RCT
12 weeks
25 female BPD patients, 
no bipolar disorder
No significant effects on 
depression, anxiety, anger, 
dissociation and global 
functioning
[23]
Zanarini et al. (2004) Fluoxetine (15 mg/day) 
versus olanzapine 
(2.5 mg/day) versus 
OFC
RCT
8 weeks
45 female BPD patients,
no affective disorder
Olanzapine and OFC greater 
than fluoxetine on impulsive-
aggression and depression
[24]
Rinne et al. (2002) Fluvoxamine 
(150–250 mg/day) 
versus placebo
RCT
6 weeks
Crossover
38 female BPD patients,
comorbidity with mood and 
anxiety disorders
↓ rapid mood shift
No effects on aggression 
and impulsivity
[25]
↓: Decrease of; ↑: Increase of; BPD: Borderline personality disorder; DBT: Dialectical behavior therapy; OFC: Combination of olanzapine and fluoxetine; PD: Personality disorder; 
RCT: Randomized controlled trial. 
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Rinne et al. tested the efficacy of fluvox­
amine (mean dose 166 mg/day) versus placebo 
in 38 female patients with BPD [25]. The study 
was a double­blind controlled trial of 6 weeks, 
followed by a 6­week crossover. Significant 
improvement was found in the scale scores for 
rapid mood shifts, with the most improvement 
in the first 6 weeks. By contrast, no difference 
between the fluvoxamine and placebo group was 
observed with regard to the effect on impulsiv­
ity and aggression scores. The authors suggested 
that effects on anger and impulsivity may be 
related to gender. 
Simpson et al. studied the effect of 12 weeks 
fluoxetine (40 mg/day) in a placebo­controlled 
trial in 25 females with BPD during dialectical 
behavior therapy (DBT) [23]. Combining fluox­
etine did not show any additional benefit on self­
report measures of depression, anxiety, anger, 
dissociation and global functioning. 
Zanarini et al. compared fluoxetine (mean 
dose 15 mg/day) with olanzapine and a com­
bination treatment of both drugs with respect 
to mood symptoms and impulsive­aggressive 
behavior in 45 female BPD patients [24]. There 
was no placebo control group. Olanzapine 
monotherapy and the combination were found 
to be superior to fluoxetine monotherapy. It is 
important to note that, for severe PD, an unusu­
ally low dose of fluoxetine was used, which might 
explain the lack of efficacy of fluoxetine. 
In summary, there is some evidence that 
SSRIs are effective in decreasing affective symp­
toms [25], specifically depressed mood [20,21], anx­
iety [20], and anger [21,22] in BPD patients. Effects 
on impulsive­aggression appear independent of 
effects on affective symptoms and may be related 
to male gender. 
  Mood stabilizers
Several RCTs have investigated the efficacy of 
mood stabilizers in treatment of affective dys­
regulation and behavioral dyscontrol of BPD 
patients (Table 3). 
Lithium 
The only RCT of lithium in BPD is reported by 
Links et al. [19]. In a crossover study, the effects 
of lithium and desipramine were compared in 
17 patients. A significant improvement of anger 
and suicidality, but not of mood symptoms, was 
found in favor of the lithium therapy. Although 
this evidence is not sufficient to support the 
indication of lithium for these patients, the risk 
of toxicity and the need for regular blood level 
controls are significant limitations to the use of 
this drug in the BPD population. 
Carbamazepine
De la Fuente and Lotstra conducted a RCT of 
carbamazepine in 20 BPD outpatients without 
any Axis I comorbidity [26]. Treatment lasted for 
31 days. Carbamazepine doses were adjusted to 
yield plasma levels in the low therapeutic range. 
There were no significant differences between 
carbamazepine and placebo on measures of affec­
tive symptoms, behavioral dyscontrol or global 
assessment. Moreover, two patients receiving 
carbamazepine dropped out because of acting 
out behaviors. Considering the limited efficacy 
on BPD symptoms shown so far by this drug 
and the risk of severe adverse effects (e.g., exac­
erbation of behavioral dyscontrol and agranu­
locitosis), it should be considered a questionable 
treatment option. 
Valproate 
Hollander et al. performed a preliminary dou­
ble­blind trial of valproate sodium (medium 
plasma concentration 80 µg/ml) in 16 BPD 
patients, f inding marked improvement in 
global symptomato logy, social functioning 
and BPD features such as depressive symp­
toms, aggressiveness, irritability and suicidal 
behavior [27]. The study suffered from a high 
drop­out rate (ten patients), which accounted 
for nonsignificant results in the intention to 
treat ana lysis. 
The same authors [28] tested valproate treat­
ment on a sample of 246 patients with a high 
degree of aggression (including BPD and other 
cluster B PDs), confirming its efficacy for 
treating impulsive­aggressive behavior. More 
recently, they reported that the effect of val­
proate in 52 BPD patients from the previous 
study, was higher among those with high trait 
impulsivity [29].
Frankenburg and Zanarini conducted a 
6­month placebo­controlled study of valproate 
sodium (plasma concentration 50–100 µg/ml) 
in 30 women with comorbidity of BPD and 
bi polar II disorder [30]. A significant improve­
ment of interpersonal sensitivity, anger, hos­
tility and aggressiveness was found in the 
valproate group. 
In conclusion, valproate is one of the more 
extensively investigated drugs for treatment of 
impulsive­aggressive behaviors in BPD. 
Neuropsychiatry (2011) 1(3) future science group264
Review Bellino, Rinaldi, Bozzatello & Bogetto
Topiramate 
Topiramate has also been investigated to test 
its ability to control aggressive behaviors in 
BPD patients. 
In the first RCT by Nickel et al. [31], 
31 women with BPD were treated with topira­
mate (50–250 mg/day) or placebo for 8 weeks. 
Topiramate was superior to placebo with respect 
to most of the State­Trait Anger Expression 
Inventory (STAXI) scales. The second topira­
mate RCT by the same group [32] included 42 
male patients and obtained approximately the 
same results. 
Follow­up studies performed by these 
authors [33–36] found that topiramate was a 
safe agent with long­lasting effects in reducing 
aggression in BPD. 
A third RCT on topiramate (25–200 mg/day 
for 10 weeks) was performed by Loew et al. in 56 
females with BPD and concurrent mood disor­
ders, finding a significant decrease of somatization 
symptoms, interpersonal sensitivity, and hostility 
and an improvement of global functioning [37]. 
Lamotrigine 
To date, only two double­blind trials of lamotrig­
ine in BPD are available. In 2005, Tritt et al. 
assessed the efficacy of lamotrigine (titrated 
to a dose of 200 mg/day) versus placebo in 
the treatment of aggression in 24 female BPD 
outpatients [38]. The study found a significant 
improvement of anger after 8 weeks of treatment. 
Moreover, during the 18­month follow­up obser­
vation, significant changes of all the scales of the 
STAXI were reported in the lamotrigine­treated 
subjects [39]. 
Reich et al. performed a 12­week double­blind 
placebo­controlled study of 28 BPD patients, 
Table 3. Double-blind randomized trials of mood stabilizers in the treatment of borderline personality disorder.
Study (year) Agents Study 
design
Subjects Results (primary outcome) Ref.
Links et al. (1990) Lithium
(986 mg/day)
versus desipramine
versus placebo
RCT 
6 weeks
Crossover
17 BPD patients,
all receving concomitant 
psychotherapy 
↓ irritability and anger 
↓ self-mutilation in favor of lithium 
No effects on mood symptoms
High rate of drop-out (10 patients)
[19]
De la Fuente and 
Lotstra (1994)
Carbamazepine
(plasma level) 
versus placebo
RCT
4.5 weeks
20 BPD outpatients, no 
Axis I comorbidity
No effects on affective symptoms, 
behavioral dyscontrol and 
global assessment
[26]
Hollander et al. 
(2001)
Valproate sodium (plasma 
level) versus placebo
RCT
10 weeks
16 BPD patients, no psychotic 
and affective disorders
No significant differences because of 
high rate of drop-out (10 patients)
[27]
Hollander et al. 
(2003)
Valproate sodium (plasma 
level) versus placebo
RCT
12 weeks
96 cluster B PDs with impulsive-
aggression (52 BPD), no 
affective disorders
↓ irritability 
↓ impulsive-aggression 
↓ global severity
[28]
Frankenburg 
and Zanarini 
(2002)
Valproate sodium (plasma 
level) versus placebo
RCT
6 months
30 female BPD patients with 
concomitant bipolar II disorder
↓ interpersonal sensitivity 
↓ anger and hostility
↓ aggressiveness
[30]
Nickel et al. 
(2004)
Topiramate
(50–250 mg/day)
versus placebo
RCT
8 weeks
31 female BPD patients ↓ irritability and anger [31]
Nickel et al. 
(2005)
Topiramate
(50–250 mg/day)
versus placebo
RCT
8 weeks
42 male BPD patients ↓ irritability and anger [32]
Loew et al. 
(2008)
Topiramate
(25–200 mg/day)
versus placebo
RCT
10 weeks
56 female BPD 
and mood disorder patients
↓ somatization symptoms
↓ interpersonal sensitivity
↓ hostility 
↑ global functioning 
[36]
Tritt et al. (2005) Lamotrigine
(50–200 mg/day)
versus placebo
RCT
8 weeks
24 female BPD patients ↓ anger [38]
Reich et al. 
(2009)
Lamotrigine 
(25–275 mg/day) 
versus placebo
RCT
12 weeks
28 BPD patients with major 
depression and anxiety 
disorders
↓ impulsivity 
↓ affective instability 
[40]
↓: Decrease of; ↑: Increase of; BPD: Borderline personality disorder; PD: Personality disorder; RCT: Randomized controlled trial.
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in order to evaluate the efficacy of lamotrigine 
in the treatment of affective instability [40]. A 
significantly greater reduction of affective insta­
bility and impulsivity was found in the group 
with lamotrigine. 
In conclusion, available studies provide initial 
evidence that the mood stabilizers topiramate, 
valproate and lamotrigine can be useful for the 
treatment of affective symptoms related to anger 
and impulsive­aggression in BPD patients. 
  Antipsychotics
Antipsychotics are widely used in clinical prac­
tice for treatment of BPD patients. RCTs have 
been performed both for classical neuroleptics 
and new generation antipsychotics, considering 
effects not only on psychotic or psychotic­like 
symptoms, but also on different dimensions of 
BPD psychopathology (Table 4). 
Classical neuroleptics
Since the 1980s, many RCTs have been con­
ducted to test the efficacy of neuroleptics such as 
flupentixol decanoate [41], loxapine, chlorproma­
zine [42], thiothixene [8], trifluoperazine [16], and 
haloperidol [17,43] in BPD patients.
In 1993, Soloff et al. performed a 5­week 
RCT of haloperidol (4 mg/day) versus the 
MAOI phenelzine (60 mg/day) and placebo 
in a large sample of BPD inpatients (n = 108), 
finding that haloperidol efficacy was limited to 
hostility and impulsive­aggressive behaviors [18]. 
Cornelius et al. followed the 54 responders of 
these 108 patients in a continuation study lasting 
16 weeks [44]. Haloperidol was prescribed up to 
a maximum of 6 mg/day, but failed to obtain 
significant effects. During prolonged haloperi­
dol treatment, depression significantly increased 
in severity and global clinical improvement was 
modest, limited to irritability. Moreover, 64% 
of patients in the haloperidol group dropped out 
during follow­up. 
In conclusion, classical neuroleptics might 
be administered to BPD patients during acute 
states with anger and psychotic­like symptoms, 
but evidence of efficacy is poor, and treatment 
should be administrated in low doses and for 
short periods because of common and remark­
able adverse effects (extrapyramidal symptoms). 
New generation antipsychotics
Several open­label studies with risperidone, clo­
zapine, and quetiapine have shown considerable 
effects on cognitive­perceptual symptoms, anger, 
and impulsivity in BPD patients. However, only 
olanzapine, aripiprazole and ziprazidone have 
been tested in RCTs. 
Olanzapine
Olanzapine has been the most thoroughly stud­
ied atypical antipsychotic in the treatment of 
BPD. Three studies investigated the effects of 
olanzapine compared with placebo. 
Zanarini and Frankenburg performed a 
6­month RCT of olanzapine (mean dose 
5.33 mg/day) in 28 women with BPD [45]. 
A signif icant improvement over placebo 
was reported in a wide range of symptoms, 
including interpersonal sensitivity, anxiety, 
anger, hostility, paranoia, psychoticism and 
global functioning. 
Bogenschutz and Nurnberg investigated 
the efficacy of olanzapine (5–10 mg/day) in 
40 BPD subjects during a 12­week RCT [46]. 
They observed a significant improvement with 
the CGI scale modified for BPD, but not with 
the Symptom Checklist­90 subscales.
In another RCT performed by Schulz 
et al., 314 patients were randomly assigned 
to olanzapine (2.5–20 mg/day) or placebo 
for 12 weeks [47]. Both groups showed a sig­
nificant improvement of BPD symptomatology 
(Zanarini Rating Scale for BPD) and did not 
differ at end point. However, time to response 
was significantly shorter for olanzapine. 
In recent years, studies comparing olanzap­
ine with other active drugs, psychotherapy, or 
their combination have been published. 
The study by Zanarini et al. comparing the 
efficacy of olanzapine (mean dose 3.3 mg/day), 
fluoxetine, and their combination has already 
been described [24].
Soler et al. [48] reported a 12­week trial of 
olanzapine (mean dose 8.83 mg/day) versus pla­
cebo in 60 BPD outpatients, who received a con­
comitant psychotherapy with DBT. Olanzapine 
was superior to placebo in reducing anxiety, 
depressive symptoms and impulsive­aggressive 
behaviors. In a following study with a similar 
design, Linehan et al. included 24 women with 
BPD, who were randomly assigned to receive 
olanzapine (mean dosage 5 mg/day) plus 
DBT or placebo plus DBT for 21 weeks [49]. 
Both groups of patients showed a considerable 
improvement of irritability, aggression, depres­
sive symptoms, and self­injury, but irritability 
and aggression scores decreased more quickly 
in the olanzapine group. 
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In a recent 8­week double­blind study com­
paring olanzapine (mean dose 7 mg/day) with 
haloperidol (mean dose 7 mg/day) in 28 female 
inpatients with BPD, Shafti and Shahveisi did 
not find significant differences between drugs 
in reducing the severity of generic behavioral 
symptoms (anxiety, depressive mood and hos­
tility subscales of the Brief Psychiatric Rating 
Scale) [50]. It must be noted that this trial did 
not use a control group with placebo. 
Aripiprazole
The only RCT of aripiprazole (15 mg/day) was 
performed by Nickel et al. in 57 BPD patients, 
and found significant effects on psychotic symp­
toms, depression, anxiety and hostility after 
8 weeks [51]. Improvements were confirmed in 
an 18­month follow­up observation study [52].
Ziprasidone
Pascual et al. included 60 BPD patients in a 
12­week placebo­controlled trial to test effi­
cacy of ziprasidone (mean dose 84 mg/day) on 
psychoticism, depression, anxiety, impulsivity 
and hostility [53]. The study failed to show any 
significant effect of ziprasidone in this sample. 
In conclusion, there is growing evidence that 
the atypical antipsychotic olanzapine signifi­
cantly improves cognitive symptoms, aggressive­
ness, anxiety and depression in BPD samples. 
Further studies are required to test the efficacy 
of newer drugs, such as aripiprazole. 
Table 4. Double-blind randomized trials of antipsychotics in the treatment of borderline personality disorder.
Study (year) Agents Study design Subjects Results (primary outcome) Ref.
Soloff et al. (1993) Haloperidol (4 mg/day) versus 
phenelzine (60 mg/day) 
versus placebo
RCT 
5 weeks
108 BPD inpatients 
with concomitant 
major depression 
↓ hostility 
↓ impulsive-aggression
[18]
Cornelius et al. (1993) Haloperidol (≤6 mg/day)
versus placebo 
RCT 
16 weeks
54 BPD outpatients, 
responders from the 
study by Soloff et al.
↓ irritability [44]
Zanarini and 
Frankenburg (2001) 
Olanzapine (5.33 mg/day) 
versus placebo 
RCT 
6 months
28 female BPD patients ↓ anger
↓ interpersonal sensitivity
↓ anxiety
↓ paranoid ideation
↑ global functioning
[45]
Bogenschutz and 
Nurnberg (2004)
Olanzapine (5–10 mg/day) 
versus placebo 
RCT 
12 weeks
40 BPD outpatients ↓ anger
↓ global symptoms 
[46]
Schulz et al. (2008) Olanzapine (2.5–20.0 mg/day) 
versus placebo 
RCT 
12 weeks
314 BPD patients No significant differences of 
BPD symptoms
Faster ↓ BPD severity in olanzapine 
group 
[47]
Soler et al. (2005) Olanzapine (5–20 mg/day) + 
DBT versus DBT + placebo 
RCT 
12 weeks
60 BPD patients ↓ anxiety 
↓ depression
↓ impulsive-aggression
[48]
Linehan et al. (2008) Olanzapine (5 mg/day) + DBT 
versus DBT + placebo 
RCT 
21 weeks
24 female BPD patients No significant differences of 
general symptoms
Faster ↓ irritability and aggression in 
the olanzapine group
[49]
Shafti and Shahveisi 
(2010)
Olanzapine (7 mg/day) 
versus haloperidol (7 mg/day)
RCT 
8 weeks
28 female BPD 
inpatients
No significant differences of generic 
behavioral symptoms
[50]
Nickel et al. (2006) Aripiprazole (15 mg/day) 
versus placebo 
RCT 
8 weeks
57 BPD patients ↓ depression and anxiety
↓ anger
↓ aggressiveness
↓ paranoia 
↑ global functioning
[51]
Pascual et al. (2008) Ziprasidone (84 mg/day) 
versus placebo 
RCT 
12 weeks
60 BPD patients No effects on psychoticism, 
depression, anxiety, impulsivity 
and hostility
[53]
↓: Decrease of; ↑: Increase of; BPD: Borderline personality disorder; DBT: Dialectical behavior therapy; RCT: Randomized controlled trial.
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  Other agents
Other psychotropic agents, such as opiate 
antagonists and omega­3 fatty acids, have been 
tested for their efficacy regarding symptoms of 
BPD (Table 5). 
One small double­blind study, including nine 
BPD patients, failed to show efficacy of intra­
venous administration of naloxone (0.4 mg) in 
the treatment of acute dissociative states [54]. 
Zanarini and Frankenberg investigated the 
effects of omega­3 fatty acids in the treatment 
of 30 female BPD patients [55]. They reported 
significant improvements in depressive symp­
toms and aggressive behaviors in response to 
ethyl­eicosapentaenoic acid (1 g/day) compared 
with placebo in an 8­week RCT. Hallahan et al. 
performed a second study evaluating 49 sub­
jects with self­harm behaviors (35 with a diag­
nosis of BPD) in a 12­week RCT [56]. Patients 
were randomized to receive eicosapentaenoic 
acid (1.2 g) plus docosahexaenoic acid (0.9 g) 
versus placebo, in addition to standard psychi­
atric care. The group receiving omega­3 fatty 
acids had significantly greater improvements in 
scales for depression, suicidality and reaction to 
daily stresses.
In conclusion, the results of these two stud­
ies are promising for treatment of mood symp­
toms and aggressive behaviors in BPD patients, 
in particular, considering the good tolerability 
of these agents. 
Treatment of antisocial PD 
Studies investigating the pharmacological treat­
ment of ASPD are scarce and involve hetero­
geneous samples (Table 6). Eight trials have been 
performed, but none of them included patients 
only on the basis of having ASPD. Most studies 
are oriented around the treatment of drug or 
alcohol abuse in ASPD patients, while no study 
focused on the disorder itself. 
Drugs compared with placebo belong to 
four categories:
  Antiepileptics: one investigation has been con­
ducted using carbamazepine [57], at a dose of 
450 mg/day for incarcerated men with aggres­
sion. No data were available for the ASPD 
subgroup in this trial. Three studies have been 
performed with phenytoin [57–59] at a dose of 
300 mg/day. Barratt reported that phenytoin 
is more effective than placebo for reducing 
frequency and intensity of aggressive behaviors 
in 126 male prisoners with impulsive­
aggression [58]. No separate results about symp­
toms of ASPD are provided by the other two 
studies [57,59]. Two controlled trials [57,60] com­
pared efficacy of valproate with placebo in out­
patients with aggression, but neither reported 
significant findings in the ASPD group.
  Antidepressants: two RCTs investigated the 
efficacy of desipramine. The first [61] included 
methadone­maintained inpatients with opioid 
and cocaine dependency, the other [62] involved 
methadone­maintained outpatients with sole 
cocaine dependence. Desipramine was not 
found superior to placebo in either study. The 
trial performed by Powell [63] in a sample of 
20 men with alcohol dependence, reported the 
efficacy of nortriptyline (25–75 mg/day) in 
reducing mean number of drinking days, level 
of anxiety, and alcohol dependence, but not 
the severity of alcohol misuse. 
  Dopamine agonists: two controlled trials have 
been published on amantadine and bromo­
criptine. In the first study [61], amantadine was 
not found superior to placebo in men with 
opioid and cocaine dependency. The study on 
bromocriptine [63] reported the efficacy of this 
drug at 15 mg/day on anxiety symptoms of 
18 men with alcohol dependency. 
Table 5. Double-blind randomized trials of opiate antagonists and omega-3 fatty acids in the treatment of borderline 
personality disorder.
Study (year) Agents Study design Subjects Results (primary outcome) Ref.
Philipsen et al. 
(2004) 
Naloxone iv. (0.4 mg) versus 
placebo
RCT 9 BPD patients No different effects on 
dissociative symptoms
[54]
Zanarini and 
Frankenberg (2003)
Ethyl-eicosapentaenoic acid 
(1 g/day) versus placebo
RCT
8 weeks
30 female BPD patients ↓ depressive symptoms
↓ aggressive behaviors
[55]
Hallahan et al. (2007) Eicosapentaenoic acid (1.2 g/day) 
plus docosahexaenoic acid 
(0.9 g/day) versus placebo
RCT
12 weeks
49 subjects with self-harm 
behaviors 
(35 BPD patients)
↓ depression and suicidality 
↓ reaction to daily stresses
[56]
↓: Decrease of; BPD: Borderline personality disorder; iv.: Intravenous; RCT: Randomized controlled trial.
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  Opioid antagonists: only one study on nal­
trexone is available in this category [64]. The 
authors compared subgroups of alcohol 
dependents with and without ASPD or BPD 
and concluded that “diagnosis of PD did not 
adversely affect alcohol outcomes, and patients 
with ASPD or BPD did not have a poorer 
response to medication” [64].
In summary, it is difficult to draw any con­
clusion about ASPD treatment from the data 
available in the literature. Only three drugs 
(nortriptyline, bromocriptine and phenytoin) 
were found superior to placebo. There is some 
evidence that nortriptyline could be useful in 
decreasing alcohol abuse of ASPD patients and 
both nortriptyline and bromocriptine are effec­
tive on anxiety symptoms in individuals with 
ASPD and alcohol dependency. There is also 
some evidence that phenytoin controls impul­
sive­aggressive behaviors in ASPD subjects. 
However, it remains unclear whether any drugs 
are effective in the treatment of core features 
of this PD.
Pharmacotherapy of cluster C PDs
  Treatment of avoidant PD
To date, no RCTs on pharmacological treat­
ment of patients with cluster C PDs have been 
published. Nevertheless, the treatment guide­
lines of the World Federation of Societies of 
Biological Psychiatry (WFSBP) [65] indicated 
the efficacy of antidepressants (SSRIs, SNRIs 
and MAOIs) for anxious/avoidant PD, on the 
basis of data concerning Axis I anxiety disorders 
like social phobia. 
  Treatment guidelines & meta-analyses
In 2001, the APA published the first set of 
guidelines for the treatment of borderline PD, 
proposing a pharmacotherapy targeted at three 
symptom dimensions: affective dysregulation, 
impulsive­behavioral dyscontrol and cognitive­
perceptual symptoms. APA guidelines and fol­
lowing updates [1,66] recommended to choose 
antidepressant agents (SSRIs and MAOIs) and 
mood stabilizers as first­ and second­line inter­
ventions for affective dysregulation, SSRIs and 
mood stabilizers for impulsive­behavioral dys­
control, and antipsychotics as first­line therapy 
for cognitive­perceptual symptoms.
In 2007, an International Task Force of the 
WFSBP [65] developed practical guidelines for 
the biological treatment of three PDs: border­
line, schizotypal and anxious/avoidant. The 
authors considered the evidence levels of each 
class of medications: level A, good research­
based evidence (at least three RCTs); level B, 
fair research­based evidence (at least two RCTs 
or one RCT and ≥1 prospective, large, open­
label study); level C, minimal research­based 
evidence (one RCT and one prospective, open­
label study/case series or at least two prospec­
tive, open­label studies/case series); level D, 
expert opinion based. The WFSBP Task Force 
recommended atypical antipsychotics for STPD 
(evidence level C) and antidepressants for 
anxious/avoidant PD (evidence level A), bas­
ing these indications only on data concerning 
Axis I anxiety disorders, like social phobia. 
Concerning BPD treatment, only evidence 
level C is achieved for antidepressants and 
mood stabilizers, while the efficacy of second­
generation antipsychotics is indicated on a fair 
research­based evidence level (level B). 
Guidelines from NICE on management of 
borderline and antisocial PDs [101,102] have a 
more prudent position and do not recommend 
drug therapy other than for treatment of mental 
disorders in comorbidity. So, they reach differ­
ent conclusions from other guidelines, despite 
considering approximately the same evidence. 
A reason for this discordance is that the NICE 
group graded available evidence as ‘low quality’. 
Table 6. Double-blind randomized trials in the treatment of antisocial personality disorder.
Study (year) Agents Study design Subjects Results Ref.
Barratt et al. 
(1997)
Phenytoin (300 mg/day)
versus placebo
RCT
9 weeks
126 male prisoners with 
impulsive-aggression
↓ aggressive behaviors [58]
Powell et al. 
(1995)
Nortriptyline (25–75 mg/day)
versus bromocriptine 
(15 mg/day)
versus placebo
RCT
4 weeks
38 male ASPD with 
alcohol dependence 
↓ drinking days, level of anxiety 
and alcohol dependence in the 
nortriptyline group
↓ anxiety symptoms in the 
bromocriptine group
[63]
↓: Decrease of; ASPD: Antisocial personality disorder; RCT: Randomized controlled trial.
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Moreover, the NICE guidelines have been 
developed looking at the care pathway within 
the NHS in England and Wales, considering 
evidence of cost–effectiveness (including evi­
dence of harm) not only for medications, but 
also for the whole range of treatments (clinical 
management and psychological therapies) [67]. 
Recently, following the growing number of 
pharmacological trials in patients with BPD, a 
few meta­analyses on BPD treatment have been 
published. One was performed by the Cochrane 
Collaboration [68] and included ten RCTs pub­
lished between 1980 and 2001, predominantly 
on classical antipsychotics and antidepressants. 
These authors did not find a good level of evi­
dence for medication efficacy in BPD. In the 
same year, a meta­ana lysis by Nosè et al. on 
22 RCTs concluded that antidepressants and 
mood stabilizers are effective against affec­
tive instability and anger, while antipsychotics 
have positive effects on impulsive­aggressive 
behaviors and global functioning [69]. In the 
systematic review by Duggan et al. on the 
pharmacological treatment of PDs, efficacy of 
atypical antipsychotics and mood stabilizers 
in improving cognitive­perceptual symptoms 
and impulsivity aggression, respectively, was 
reported [70]. Recently, results of meta­analy­
ses and conclusions of systematic reviews have 
indicated a noticeable shift from the choice of 
antidepressants to mood stabilizers and second­
generation antipsychotics in the treatment of 
BPD [71]. Few reviews tried to summarize avail­
able data providing indications focused on APA 
or similar dimensions of BPD psychopathology.
In a meta­ana lysis concerning efficacy of 
medications on anger and depression in BPD 
patients, Mercer et al. suggested that mood sta­
bilizers should be considered as first­line ther­
apy for anger and affective symptoms, rather 
than SSRIs [72]. Antipsychotics were found to 
have a medium effect on symptoms of anger 
and no effects on depression. Ingenhoven et al. 
evaluated the efficacy of pharmacotherapy for 
borderline and schizotypal PDs on specific tar­
get domains: cognitive­perceptual symptoms, 
impulsive­behavioral dyscontrol, affective dys­
regulation (depressed mood, anxiety, anger 
and mood lability) and global functioning [73]. 
Mood stabilizers had positive effects on global 
functioning, impulsive­behavioral dyscontrol, 
anger and anxiety. Antipsychotics had a mod­
erate effect on cognitive symptoms and anger. 
Antidepressants were not found to be effective 
on impulsive­behavioral dyscontrol and mood 
symptoms, but they had a small effect on anxi­
ety and anger. Saunders and Silk collected and 
analyzed data from placebo­controlled trials 
on treatment of BPD, sorting target symptoms 
into the trait dimensions of affective instability, 
anxiety inhibition, cognitive­perceptual distur­
bances and impulsivity aggression [74]. They 
found that antipsychotics had the strongest 
evidence for all dimensions. 
According to the Cochrane Systematic 
Review of pharmacological interventions for 
BPD [75], the available evidence indicates that 
mood stabilizers, second­generation antipsy­
chotics, and omega­3 fatty acids may be effec­
tive for treating specific BPD symptoms. The 
use of anti depressants is supported by data only 
in patients with concomitant depression.
Findings from these studies raise consider­
able questions on the decisional trees proposed 
by APA guidelines [1]. In particular, the rec­
ommendation to administer SSRIs or related 
antidepressants to treat affective dysregulation 
and impulsive­behavioral dyscontrol should be 
reconsidered on the basis of more recent results. 
Conclusion & future perspective
In recent years a growing number of trials 
on the pharmacological treatment of PDs, 
in particular of BPD, have been performed. 
Nevertheless, available studies from important 
methodological limitations, such as a small 
number of patients, samples made of only 
male or female gender, heterogeneous selec­
tion criteria and outcome measures, and high 
rates of drop­outs. Moreover, the duration of 
trials is usually short and no conclusions can 
be drawn on the long­term use of medications 
in these patients. 
Despite these limitations, the review of the 
RCTs published from 1990 to 2010 provided 
some evidence of the efficacy of certain medi­
cations to treat specific symptoms of border­
line PDs. Proposing indications on drug treat­
ment of other PDs is more difficult and poorly 
reliable because available data are sparse. 
Preliminary studies performed with anti­
psychotics in patients with schizotypal PD 
suggested a reduction of psychotic­like 
symptoms. 
However, some subjects included in these 
trials had concomitant BPD and it remains 
unclear whether reported improvements were 
due to the effects of medications on BPD­related 
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symptoms. Furthermore, drugs were used at low 
doses to minimize considerable sensitivity to 
side effects in this population. Although anti­
psychotics may reduce clinical symptoms, they 
do not induce a substantial benefit for cognitive 
performance of individuals with STPD. Recent 
trials suggested an improvement of cognitive 
performance in these patients (e.g., working 
memory and context processing) using dopa­
mine and adrenaline agonists, but these agents 
are not currently used in clinical practice. 
Concerning treatment of antisocial PD, 
there is initial evidence that nortriptyline and 
bromocriptine could produce some effects in 
individuals with concurrent alcohol depen­
dence, while phenytoin seems to reduce 
impulsive­aggressive behaviors. However, it is 
questionable whether any drug is effective in 
the treatment of core features of ASPD.
Investigations on psychotropic agents in the 
treatment of BPD have recently tested several 
drugs belonging to the classes of antidepressants, 
mood stabilizers and antipsychotics. 
In summary, there is some evidence that 
SSRIs are effective in decreasing depressed 
mood, anxiety, and anger in BPD patients, 
in particular when comorbidity with affective 
disorders is present. Many authors retain that 
prescription of SSRIs should be reserved for 
treatment of a comorbid major depressive epi­
sode, rather than BPD affective dysregulation 
itself [65,73,75]. Effects of SSRIs on impulsive­
aggression have less support and may be limited 
to male gender. Concerning mood stabilizers, 
available studies provide evidence that topira­
mate, valproate and lamotrigine can be useful 
for the treatment of affective symptoms related 
to anger and impulsive­behavioral dyscontrol 
in BPD patients. These agents also appear to 
have significant effects on global functioning. 
As for second­generation antipsychotics, there 
is growing evidence from RCTs that olanzap­
ine significantly improves cognitive symptoms, 
anger, anxiety and depression in BPD. Further 
controlled studies are needed to confirm the 
efficacy of newer drugs, such as aripiprazole.
Balancing the evidence of efficacy against 
adverse effects, some authors retain that dietary 
supplementation by omega­3 fatty acids could 
also be considered as an option to treat mood 
symptoms and impulsive­aggressive behaviors. 
In conclusion, a pharmacotherapy targeted 
on well­defined symptom domains of BPD 
can be effective in improving some features 
of the clinical picture, but no medication is 
indicated to perform a global treatment of the 
disorder itself. 
Most clinical trials testing the eff icacy 
of drugs in BPD patients provide results on 
change of single symptoms or clusters of symp­
toms. Even if APA guidelines recommend a 
dimensional treatment of BPD, dimensions are 
usually not considered in single trials, mainly 
because authors do not choose dimensional 
instruments to evaluate outcome. There is the 
need for a more clear distinction of the two 
concepts of symptoms and dimensions in both 
research and clinical application. 
Concerning the applicability of data from 
RCTs to clinical practice, we should not under­
estimate the differences between study samples 
and clinical populations. In fact, patients in 
clinical populations are not selected on the basis 
of inclusion/exclusion criteria. So, the level of 
social dysfunction and the frequency of Axis I 
and II comorbidity (in particular with mood 
disorders) are likely higher in usual practice. 
Moreover, patients with PDs present impulsive­
behavioral dyscontrol and poor compliance 
and adherence. Therefore, clinicians prescrib­
ing medications should carefully inform and 
monitor them, in order to minimize the risk 
of intoxication, abuse, self­poisoning and side 
effects. As stated in the NICE guidelines and 
reported in a previous review by our group [76], 
some of the drugs administered to PD patients 
are potentially harmful: for example, valproate 
semisodium is potentially dangerous for women 
of child­bearing age, who are the largest pro­
portion of BPD patients in clinical practice 
and often do not adopt adequate birth control 
methods; and antipsychotics can induce serious 
neurological and metabolic side effects [67]. It 
should also be stressed that drugs potentially 
fatal in overdose must be used with great cau­
tion in PD patients at risk of suicide [1]. Thus, 
tolerability profile, characteristics of patients 
and evidence of efficacy should be carefully 
examined and balanced before prescribing 
medications to PD patients. Another remark­
able difference between trials and clinical prac­
tice is that patients included in study samples 
are usually treated with selected doses of a 
single therapeutic agent, while those observed 
in the usual clinical settings are more com­
monly treated with multiple medications and 
psychotherapy at the same time. So, further 
investigations focused on associations of drugs 
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and combination of medications and psycho­
social interventions are required to collect data 
that can be more easily and reliably applied to 
everyday patients. 
As repeatedly suggested in this article and 
by others [70–74], future perspectives of research 
should focus on a series of core topics: large­
scale multicenter RCTs of mood stabilizers and 
new anti psychotics in order to confirm prelimi­
nary evidence; drug­to­drug comparisons (e.g., 
atypical vs traditional antipsychotics, different 
mood stabilizers) to explore differential effects 
of medications; fixed­dosage and long­term 
studies in order to determine appropriate doses 
and duration of treatments; identification of 
biological, clinical and pharmaco logical fac­
tors that predict response to drug treatments; 
assessment of results of combined therapy 
in comparison with single pharmaco­ and 
psychotherapy; and selection of a set of out­
come measures that can be retained reliable 
and specific to test drug efficacy and safety in 
BPD populations.
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